FindTrial
Sign In

Role of USP25 regulating STAT3-dependent anti-inflammatory pathway of IL-10 / IL-22 in ulcerative colitis and its mechanism

Role of USP25 regulating STAT3-dependent anti-inflammatory pathway of IL-10 / IL-22 in ulcerative colitis and its mechanism

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900021015
Enrollment
Unknown
Registered
2019-01-25
Start date
2019-02-10
Completion date
Unknown
Last updated
2019-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis

Interventions

Chort 1 Patents with ulcerative colitis:N/A
Chort 2 Healthy people:N/A

Sponsors

Renmin Hospital of Wuhan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 80 years; 2. Positive diagnosis of ulcerative colitis and patients without ulcerative colitis; 3. Patients who agree for participating in the clinical trail and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Severe respiratory and cardiovascular diseases; 2. Severe liver damage; 3. Severe renal impairment; 4. Malignancy; 5. Bleeding disorders; 6. Severe systemic infection; 7. pregnancy or prepare to be pregnancy or lactation; 8. Not suitable for the clinical trail.

Design outcomes

Primary

MeasureTime frame
USP25 DNA;USP25 protein;IL-10;IL-22;—

Secondary

MeasureTime frame
IL-6;TNF-a;IFN-?;—

Countries

China

Contacts

Public ContactWeiguo Dong

Renmin Hospital of Wuhan University

dwg@whu.edu.cn+86 13986167388

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026